Hosted on MSN2d
New CAR T-Cell Therapy Approved for LeukemiaThe FDA approved obecabtagene autoleucel (obe-cel; Aucatzyl) for treating relapsed or refractory B-cell precursor acute ...
Scientists from Duke-NUS Medical School and their collaborators have identified an inherited genetic variation prevalent ...
Of these, chronic myeloid leukemia (CML) is a subtype that primarily affects the bone marrow, which produces blood cells. The Duke-NUS scientists, in collaboration with their partners, including ...
The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based ...
T cells in patients with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL). T-ALL, known for its challenging ...
These findings suggest that KIR2DS2-positive (KIR2DS2+) natural killer (NK) cells could be an attractive therapeutic target ...
FDA approves Autolus Therapeutics' Aucatzyl for adults with relapsed or refractory B-cell precursor acute lymphoblastic ...
Obecabtagene autoleucel (obe-cel; Aucatzyl) has been approved by the FDA to treat patients with relapsed or refractory B-cell ...
Single-cell analysis of CML patients bone marrow at diagnosis reveals coexistence of CD26-CD35+ healthy stem cells and CD26+CD35- CML stem cells, and how the ratio between these impacts TKI response.
CAR-T cell therapy, a marvel of bioengineering, takes a patient’s own immune cells and reprograms them to attack cells ...
Partow Kebriaei, MD, discusses when the optimal time for transplant is in patients with acute lymphoblastic leukemia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback